Cambridge Consultants has reinvested in gene synthesis platform developer Evonetix, helping it increase its lifetime funding to $46m.

UK-based gene synthesis technology developer Evonetix completed a $30m series B round yesterday backed by product development and technology consultancy firm Cambridge Consultants.

Investment firm Foresite Capital led the round, which included Morningside Group, Civilization Ventures, Draper Esprit, Providence Investment Company, Rising Tide Fund and Data Collective (DCVC).

Evonetix is working on a desktop platform that will enable DNA to be synthesised on thousands of sites across a silicon array simultaneously, meaning longer DNA strands can be synthesised more quickly…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?